Happy New Year, everyone! First paper to share in 2026: (finally) a mechanistic study of cancer microbiome! pks+ E. coli's colibactin binds AT-rich DNA in minor groove and induces cross-links in colorectal cancer cells #microsky #microbiomesky 🧪🦠
www-science-org.remotexs.ntu.edu.sg/doi/10.1126/...

Patients with a history of GLP-1 receptor agonist treatment had a significantly lower risk of developing colorectal cancer (CRC) as compared with those who took aspirin, according to a study reported at @ascocancer.bsky.social #GI26.

https://www.medpagetoday.com/meetingcoverage/ascogi/119302?trw=no

“With big data there are a lot of opportunities but also challenges: w/ so much data coming in how do you separate signal from noise?” asked 1st panelist Dr. Caroline Chung @ #GI26 Intersections Session on harnessing #AI for managing GI cancers happening now. #gicsm meetings.asco.org/meetings/202...

Can #AI help improve conduct of #cancer #clinicaltrials?

🍔A study found higher fast-food spending by block in Alabama was linked to more cases of early-onset colorectal cancer, while higher fruit & vegetable spending had a strong protective effect.🥦
🔹 Blake Buchalter, MPH, PhD
🔗 https://ow.ly/urH650XT29I

Happy to be at #GI26! Hoping to learn the current status of #colorectal #cancer research. @ascocancer.bsky.social @fightcrc.bsky.social

Key Takeaways from.Dr. @fumikochino.bsky.social on avoiding or mitigating the financial toxicity of cancer treatment
#ASCO25
#FinancialToxicity
#ayacsm

#ASCO25 session “AI in Cancer Care: The Evolving Role of Decision Support in Care Delivery and Practical Application in Your Practice” highlighted both the promise and the challenges—plus our new AI tool “ASCO Guidelines Assistant”.

Learn more: www.asco.org/practice-pat...

Dr. Fumiko Chino presented at #ASCO25 that most patients want to talk about the cost of cancer care, but very few do.

Understanding and addressing cost concerns is an important part of supporting patients through treatment. #EndCancer @fumikochino.bsky.social

Enco/cet + mFOLFOX6 is the new standard 1L for BRAF V600E mut mCRC patients
➡️ mPFS: 12.8 vs 7.1 mos
➡️ mOS: 30.3 vs 15.1 mos

#ASCO25 @ascocancer.bsky.social